139 related articles for article (PubMed ID: 3904585)
21. [The analysis of tumor growth rate and histopathology of xenografts of nude mice bearing human ovarian carcinoma in immunocompetent mice].
Wang J; Qian H; Li W
Zhonghua Fu Chan Ke Za Zhi; 1995 Mar; 30(3):157-60. PubMed ID: 7796649
[TBL] [Abstract][Full Text] [Related]
22. [Applicability of the subrenal capsule assay (SRCA) in primary breast carcinoma].
Gerber B; Richter D; Rohde E; Wilken H; Rudolf K; Kasch R
Arch Geschwulstforsch; 1989; 59(2):85-91. PubMed ID: 2541670
[TBL] [Abstract][Full Text] [Related]
23. Accurate predictions of tumor growth in vivo: the subrenal capsule implant site.
Stratton JA; Rettenmaier MA; Braly PS; DiSaia PJ
J Biol Response Mod; 1983; 2(3):272-9. PubMed ID: 6644340
[TBL] [Abstract][Full Text] [Related]
24. [Subrenal capsule assay for testing the effectiveness of anticancer drugs].
Nemoto R; Uchida K; Shimazui T; Ishikawa S; Koiso K
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1235-40. PubMed ID: 3729447
[TBL] [Abstract][Full Text] [Related]
25. [Analysis of clinical responses in comparison with the results of the chemosensitivity test by subrenal capsule assay].
Inoue K; Wang Y; Itoh Y; Shibata H; Chen SC; Ogawa M
Gan To Kagaku Ryoho; 1987 Jul; 14(7):2305-9. PubMed ID: 3606150
[TBL] [Abstract][Full Text] [Related]
26. Similarities and differences in the ultrastructure of two hormone-dependent and one independent human breast carcinoma grown in athymic nude mice: comparison with the rat DMBA-induced tumor and normal secretory mammocytes.
Anderson WA; Perotti ME; McManaway M; Lindsey S; Eckberg WR
J Submicrosc Cytol; 1984 Oct; 16(4):673-90. PubMed ID: 6438351
[TBL] [Abstract][Full Text] [Related]
27. Methodological aspects of the 6-day subrenal capsule assay for measuring the response of human tumors to anticancer agents.
Aamdal S; Fodstad O; Pihl A
Anticancer Res; 1985; 5(4):329-37. PubMed ID: 4037730
[TBL] [Abstract][Full Text] [Related]
28. The human tumour colony-forming assay using fresh specimens.
Slee PH; Van Oosterom AT; Van den Berg L; De Bruijn EA
Neth J Med; 1986; 29(6):180-8. PubMed ID: 3016578
[No Abstract] [Full Text] [Related]
29. [Experimental study of the 6-day subrenal capsule assay by cyclophosphamide pretreatment].
Terashima M; Ikeda K; Kawamura S; Satoh M; Ishida K; Amano K; Takagane A; Yaegashi Y; Saitoh K
Gan To Kagaku Ryoho; 1988 Mar; 15(3):505-11. PubMed ID: 3348636
[TBL] [Abstract][Full Text] [Related]
30. Activity of mitozolomide (NSC 353451), a new imidazotetrazine, against xenografts from human melanomas, sarcomas, and lung and colon carcinomas.
Fodstad O; Aamdal S; Pihl A; Boyd MR
Cancer Res; 1985 Apr; 45(4):1778-86. PubMed ID: 3978640
[TBL] [Abstract][Full Text] [Related]
31. [Comparison of human tumor clonogenic and nude mouse-isotope assays in anticancer-agent sensitivity tests].
Hirabayashi N; Nosoh Y; Nishiyama M; Yamaguchi M; Yoshinaka K; Niimoto M; Hattori T
Gan To Kagaku Ryoho; 1985 Sep; 12(9):1808-12. PubMed ID: 3929691
[TBL] [Abstract][Full Text] [Related]
32. The subrenal capsule assay in immunocompetent mice--the inevitable role of histopathology in assessment of this method as a tool determining tumor sensitivity to cytostatic drugs.
Marek J; Bechynĕ M
Neoplasma; 1990; 37(1):23-30. PubMed ID: 2320176
[TBL] [Abstract][Full Text] [Related]
33. [Subrenal capsule (SRC) assay as a chemosensitivity test (IV)--Evaluation of the SRC assay method as a system for growing implanted tumor-xenografts].
Kusuyama T; Fujita M; Shimozuma K; Taguchi T
Gan To Kagaku Ryoho; 1987 Nov; 14(11):3105-13. PubMed ID: 3674896
[TBL] [Abstract][Full Text] [Related]
34. [Determination of the individual sensitivity of human stomach cancer cells to fluoropyrimidines by the cytomorphological criteria of heterotransplants in diffusion chambers].
Zhero SV; Ganina KP
Eksp Onkol; 1986; 8(6):57-62. PubMed ID: 3100269
[TBL] [Abstract][Full Text] [Related]
35. In vivo antineoplastic activity of ascorbic acid for human mammary tumor.
Tsao CS; Dunham WB; Leung PY
In Vivo; 1988; 2(2):147-50. PubMed ID: 2979831
[TBL] [Abstract][Full Text] [Related]
36. Response of ovarian cancer to combined cytotoxic agents in the subrenal capsule assay: Part I.
Mäenpää J; Kangas L; Grönroos M
Obstet Gynecol; 1985 Nov; 66(5):708-13. PubMed ID: 3932908
[TBL] [Abstract][Full Text] [Related]
37. Characterization of a preclinical model of simultaneous breast and ovarian cancer progression.
Ting AY; Kimler BF; Fabian CJ; Petroff BK
Carcinogenesis; 2007 Jan; 28(1):130-5. PubMed ID: 16891317
[TBL] [Abstract][Full Text] [Related]
38. The growth and therapeutic response of human tumours in immune deficient mice.
Steel GG
Bull Cancer; 1978; 65(4):465-72. PubMed ID: 371709
[TBL] [Abstract][Full Text] [Related]
39. Brain tumor growth and response to chemotherapy in the subrenal capsule assay.
Weizsäcker M; Nagamune A; Rathmer K; Wechsler W
J Cancer Res Clin Oncol; 1983; 106(3):229-33. PubMed ID: 6654957
[TBL] [Abstract][Full Text] [Related]
40. Preclinical evaluation of the breast cancer cell-binding peptide, p160.
Askoxylakis V; Zitzmann S; Mier W; Graham K; Krämer S; von Wegner F; Fink RH; Schwab M; Eisenhut M; Haberkorn U
Clin Cancer Res; 2005 Sep; 11(18):6705-12. PubMed ID: 16166451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
